Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?

Digestive Diseases

Volumn 32, Issue 1-2, 2014, Pages 156-163

  Spechler, Stuart Jon ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Antireflux surgery; Barrett's esophagus; Gastroesophageal reflux disease; Proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR; OMEPRAZOLE;

ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; CALCIUM METABOLISM; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DNA DAMAGE; EPITHELIUM CELL; FOOD ALLERGY; GASTROESOPHAGEAL REFLUX; HUMAN; INTERSTITIAL NEPHRITIS; MAGNESIUM METABOLISM; MICROSCOPIC COLITIS; OBSERVATIONAL STUDY; PATIENT CARE; PRIORITY JOURNAL; SECRETION (PROCESS); STOMACH ACID; CELL PROLIFERATION; CHEMOPROPHYLAXIS; ESOPHAGITIS; ESOPHAGUS SURGERY; INFECTION; REFLUX ESOPHAGITIS; REMISSION; STOMACH ACID SECRETION;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; REMISSION INDUCTION;

EID: 84896123580     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000357184     Document Type: Article

References (59)

1. Spechler SJ: Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310: 627-636.
2. Burke ZD, Tosh D: Barrett's metaplasia as a paradigm for understanding the development of cancer. Curr Opin Genet Dev 2012; 22: 494-499.
3. Gurski RR, Peters JH, Hagen JA, DeMeester SR, Bremner CG, Chandrasoma PT, De-Meester TR: Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 2003; 196: 706-713. (Pubitemid 36560200)
4. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, Kleibeuker JH: Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 489-494. (Pubitemid 29447813)
5. Haag S, Nandurkar S, Talley NJ: Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc 1999; 50: 229-240. (Pubitemid 29380371)
6. Macarthur M, Hold GL, El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004; 286:G515-G520. (Pubitemid 38374969)
7. Katz PO, Gerson LB, Vela MF: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-328.
8. Zhang HY, Hormi-Carver K, Zhang X, Spechler SJ, Souza RF: In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res 2009; 69: 9083-9089.
9. Mills KD, Ferguson DO, Alt FW: The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev 2003; 194: 77-95. (Pubitemid 36886430)
10. Fitzgerald RC, Omary MB, Triadafilopoulos G: Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 2120-2128. (Pubitemid 26376301)
11. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary B, Triadafilopoulos G: Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-496. (Pubitemid 30140846)
12. Souza RF, Shewmake K, Terada LS, Spechler SJ: Acid exposure activates the mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299-307. (Pubitemid 34126346)
13. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G: Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335. (Pubitemid 29352940)
14. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Karrenbeld A, de Jager-Krikken A, Klinkenberg-Knol EC, Lamers CB, Kleibeuker JH: Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 2000; 35: 1238-1244. (Pubitemid 32051635)
15. Feagins LA, Zhang HY, Hormi-Carver K, Quinones MH, Thomas D, Zhang X, Terada LS, Spechler SJ, Ramirez RD, Souza RF: Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 2007; 102: 10-20. (Pubitemid 46072037)
16. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ: Gastroesophageal reflux may cause esophagitis through a cytokine-mediated mechanism, not by caustic (acid) injury. Gastroenterology 2009; 137: 1776-1784.
17. Huo X, Zhang X, Yu C, Zhang Q, Cheng E, Wang DH, Pham TH, Spechler SJ, Souza RF: In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-κB and activator protein-1. Gut, DOI: 10.1136/gutjnl-2013-305533.
18. Pohl H, Sirovich B, Welch HG: Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010; 19: 1468-1470.
19. Huo X, Juergens S, Zhang X, Rezaei D, Yu C, Strauch ED, Wang JY, Cheng E, Meyer F, Wang DH, Zhang Q, Spechler SJ, Souza RF: Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol 2011; 301:G278-G286.
20. Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW: Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006; 101: 1964-1971. (Pubitemid 44337617)
21. Spechler SJ: Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310: 627-636.
22. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E: Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-1370. (Pubitemid 23235408)
23. Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, DeMeester SR, Bremner CG, DeMeester TR, Peters JH: Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000; 4: 50-54.
24. Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, Varro A, Dimaline R: Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124: 615-625. (Pubitemid 36268480)
25. Williams C, McColl KE: Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23: 3-10. (Pubitemid 43381161)
26. Kuipers EJ: Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes? Basic Clin Pharmacol Toxicol 2006; 99: 187-194. (Pubitemid 44289740)
27. Bavishi C, Dupont HL: Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269-1281.
28. de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD, Kusters GC, Laheij RJ: Proton pump inhibitor therapy predisposes to communityacquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012; 36: 941-949.
29. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN: Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a metaanalysis. Am J Gastroenterol 2012; 107: 1001-1010.
30. Lo WK, Chan WW: Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 483-490.
31. Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, Rolston DD, Sferra TJ, Hernandez AV: Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol 2013; 28: 235-242.
32. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group: The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 2013; 24: 1161-1168.
33. Quasdorff M, Mertens J, Dinter J, Steffen HM: Recurrent hypomagnesemia with protonpump inhibitor rechallenge. Ann Intern Med 2011; 155: 405-407.
34. Sierra F, Suarez M, Rey M, Vela MF: Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007; 26: 545-553. (Pubitemid 47174291)
35. Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA: Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010; 32: 1124-1128.
36. Merwat SN, Spechler SJ: Might the use of acid suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol 2009; 104: 1897-1902.
37. Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ: Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2013; 2:e004564.
38. Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, Hansen PR, Madsen JK, Kober L, Torp-Pedersen C, Gislason G: Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010; 153: 378-386.
39. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE: Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-1883. (Pubitemid 39421227)
40. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE: Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7: 1299-1304.
41. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC: Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 387-391. (Pubitemid 38528957)
42. Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, Bruno MJ, ProBar Study Group: Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013; 11: 382-388.
43. DeMeester SR, DeMeester TR: Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg 2000; 231: 303-321.
44. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D: The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93: 536-541. (Pubitemid 29080999)
45. Oberg S, Wenner J, Johansson J, Walther B, Willen R: Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005; 242: 49-54. (Pubitemid 40917967)
46. Richter JE: Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol 2013; 11: 465-471.
47. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W: Long-term outcome of medical and surgical treatments for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-2338. (Pubitemid 32424101)
48. Parrilla P, Martinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M: Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-298. (Pubitemid 38176442)
49. Corey KE, Schmitz SM, Shaheen NJ: Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003; 98: 2390-2394. (Pubitemid 37448746)
50. Chang EY, Morris CD, Seltman AK, O'Rourke RW, Chan BK, Hunter JG, Jobe BA: The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg 2007; 246: 11-21. (Pubitemid 47012200)
51. Ye W, Chow WH, Lagergren J, Yin L, Nyren O: Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121: 1286-1293. (Pubitemid 33140445)
52. Tran T, Spechler SJ, El-Serag HB: Fundoplication and the risk of cancer in gastroesophageal reflux disease: a veterans affairs cohort study. Am J Gastroenterol 2005; 100: 1002-1008. (Pubitemid 40769033)
53. Lagergren J, Ye W, Lagergren P, Lu Y: The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology 2010; 138: 1297-1301.
54. Drewitz DJ, Sampliner RE, Garewal HS: The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212-215. (Pubitemid 27076463)
55. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-338. (Pubitemid 30621983)
56. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, Howden CW: The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012; 61: 970-976.
57. Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, Singh M, Singh V, Chuang KY, Boolchand V, Gavini H, Kuczynski J, Sud P, Reddymasu S, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Lieberman DA, Sampliner RE, Sharma P: Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227.
58. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ: Risk of malignant progression in Barrett's esophagus patients: results from a large populationbased study. J Natl Cancer Inst 2011; 103: 1049-1057.
59. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P: Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365: 1375-1383.